Synergetic effects of doxycycline-loaded chitosan nanoparticles for improving drug delivery and efficacy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2411-2419

  Cover, Natasha F ^a   Lai Yuen, Susana ^b   Parsons, Anna K ^c   Kumar, Arun ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b University of South Florida   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF DELAWARE   (United States)

Author keywords

Chitosan; Cytotoxicity; Doxycycline; Ionic gelation; Nanoparticles

Indexed keywords

CHITOSAN; DOXYCYCLINE; NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; EPITHELIUM CELL; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE;

ANTI-BACTERIAL AGENTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; DOXYCYCLINE; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PARTICLE SIZE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 84870381564     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27328     Document Type: Article

References (41)

1. Crossman SH. The challenge of pelvic inflammatory disease. Am Fam Physician. 2006;73(5):859-864.
2. Haggerty CL, Ness R. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis. 2007;44(7):953-960.
3. Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2007;44(Suppl 3):S111-S122.
4. Sweet R. Role of bacterial vaginosis in pelvic inflammatory disease. Clin Infect Dis. 1995;20(2):271-275.
5. Peterson HB, Galaid EI, Zenilman JM. Pelvic inflammatory disease: review of treatment options. Rev Infect Dis. 1990;12(6):656-664.
6. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct cost of pelvic inflammatory disease and its sequelae: decreasing but still substantial. Obstet Gynecol. 2000;95(3):397-402.
7. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR. 2010;59(RR-12):1-109.
8. Riond J, Riviere J. Pharmacology and toxicology of doxycycline. Vet Hum Toxicol. 1988;30(5):431-443.
9. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med. 1997; 157(13):1421-1428.
10. Cunha BA, Domenico P, Cunha CB. Pharmacodymanics of doxycycline. Clin Microbiol Infect. 2001;6(5):270-273.
11. Gencosmanoglu R, Kurtkaya-Yapicier O, Tiftikci A, Avsar E, Tozun N, Oran ES. Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline or doxycycline-induced esophageal injury. J Clin Gastroenterol. 2004;38(6):484-489.
12. Morris TJ, Davis TP. Doxycycline-induced esophageal ulceration in the US Military service. Mil Med. 2000;165(4):316-319.
13. Tahan V, Sayrak H, Bayar N, Erer B, Tahan G, Dane F. Doxycycline-induced ulceration mimicking esophageal cancer. Cases J. 2008;1(1):144.
14. Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest. 1994;105(6):1743-1747.
15. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis Suppl. 1988;53:29-34.
16. Robinson LA, Fleming WH, Galgraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg. 1993; 55(5):1115-1121.
17. Hurewitz AN, Lidonicci K, Wu CL, Zucker S. Histologic changes of doxycycline pleurodesis in rabbits. Effect of concentration and pH. Chest. 1994;106(4):1241-1245.
18. Pulsiripunya C, Youngchaiyud P, Pushpakom R, Maranetra N, Nana A, Charoenratanakul S. The efficacy of doxycycline as a pleural sclerosing agent in malignant pleural effusion: a prospective study. Respisology. 1996;1(1):69-72.
19. Venugopal P. Medical pluerodesis. Pulmon. 2007;9(2):51-56.
20. Davies RP, McClymont T, Boshell D. Utlrasound guided chemicalpluerodesis with doxycycline. Diagn Ultrasound. 2005;8(3):23-27.
21. Zhang H, Wu S, Tao Y, Zang L, Su Z. Preparation and characterization of water-soluble chitosan nanoparticles as protein delivery system. J Nanomater. 2009;2010:1-5.
22. Muhammed R, Junise V, Saraswathi P, Krishnan P, Dilip C. Development and characterization of chitosan nanoparticles loaded with isoniazid for the treatment of tuberculosis. Res J Pharm Biol Chem Sci. 2010;1(4):383-390.
23. Phaechamud T, Charoenteeraboon J. Antibacterial activity and drug release of the chitosan sponge containing hyclate. AAPS Pharm Sci Tech. 2008;9(3):829-835.
24. Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm. 2002;249(1-2):165-174.
25. Xi-Peng G, Da-Ping Q, Kai-Rong L, Tao W, Peng X, Mai KC. Preparation and characterization of cationic chitosan-modified poly(D, L-lactide-co-glycolide) copolymer nanospheres as DNA carriers. J Biomater Appl. 2008;22(4):353-371.
26. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticle. Colloids Surf B Biointerfaces. 2006;53(2):193-202.
27. Goycoolea FM, Lollo G, Remunan-Lopez G, Quaglia F, Alonso MJ. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules. 2009;10(7):1736-1743.
28. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res. 1999;16(12):1830-1835.
29. Shanmuganathan S, Shanumugasundaram N, Adhirajan N, Ramyaa-Lakshmi TS, Babu M. Preparation and characterization of chitosan microsphere for doxycycline delivery. Carbohydrate Polymers. 2007; 73(2):201-211.
30. Mohanraj VJ, Chen Y. Nanoparticle: a review. Trop J Pharm Res. 2006; 5(1):561-573.
31. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21.
32. Wang JJ, Zeng ZW, Xiao RZ, etal. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765-774.
33. Racovita S, Vasiliu S, Popa M, Luca C. Polysaccharides based on micro-and nanoparticles obtained by ionic gelation and their application as drug delivery systems. Revue Roumaine de Chimie. 2009;54(9):709-718.
34. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan Uni J. 2003;11(3):51-66.
35. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100(1):5-28.
36. Nagpa K, Kumar-Singh S, Nath-Mishr D. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull. 2010;58(11):1423-1430.
37. Grenha A, Seijo B, Serra C, Remunan-Lopez C. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules. 2007;8(7):2072-2079.
38. Clavo P, Vila-Jato J, Alonso MJ. Evalution of catonic polymer coated nanocapsules as ocular drug carriers. J Pharma. 1997;153(1):41-50.
39. Mehrotra A, Nagarwal RC, Kumar-Pandit J. Lomustine loaded chitosan nanoparticles: characterization and in-vitro cytotoxicity on human lung cancer cell line L13. Chem Pharm Bull. 2011;59(3):315-320.
40. Alameh M, Jean M, DeJesus D, Buschmann MD, Merzouk A. Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing. Int J Nanomedicine. 2010;5:473-481.
41. Lee YS, Jang KA, Cha JD. Synergistic antibacterial effect between silibinin and antibiotics in oral bacteria. J Biomed Biotechnol. 2012:article ID 618081.